Health Care

Insider buying at Oncology Institute Inc. shows new bullish confidence—17,185 shares, no cash, and a strong balance sheet—hinting at future upside in oncology services.

Insight: MEDTRONIC SVP Walter Matthew R’s modest July 8 sale shows routine liquidity management, not a warning – investors can still focus on the firm’s steady product pipeline and market stability.

Elanco CFO sells 15k shares: a liquidity move, not a confidence shift—insider buying stays strong, showing long‑term support for the company.

Curis insider Rubin Marc buys 6,800 shares at $5.29, signaling confidence in the company’s regenerative pipeline despite negative sentiment and upcoming option dilution.

NewGenIVF’s CEO buys 73,647 employee options, signaling strong leadership confidence and a bullish outlook for the biotech’s future growth.

Tonix CFO’s June 30 buy of 1,453 shares at $10.91 signals growing insider confidence amid a volatile market, hinting at future upside for investors.

CEO Michael Farrell’s disciplined 10b5‑1 trades reveal ResMed’s growth confidence: buying below $150, selling near $220, amid strategic sales and acquisitions that bolster future cash flow and share‑buybacks.

Concord Medical CFO keeps 477,000 shares steady, signaling confidence amid a volatile market and hinting at future growth opportunities.

GLAUKOS CFO’s mixed buy‑sell trade shows bullish confidence in the glaucoma therapy stock, hinting at future upside despite its negative P/E.

Explore the implications of Navratil Tomas’s recent Glaukos insider sale—understand the impact on liquidity, investor sentiment, and the company’s growth outlook.